Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of ...

Because of the patent cliff issue, companies are looking outwards. They’re buying other companies, especially those with cool new science, or forming alliances. This helps them fill the gap in their ...

Spread the loveAs the pharmaceutical industry continues to evolve, marketers find themselves at the forefront of significant changes that could redefine drug pricing, patient engagement, and overall ...

The rise of AI has powered a wave of interest in digital innovation within pharma. But to have a lasting impact, AI — like any innovation in digital health — must be able to deliver value by being ...

At Davos this year, AI was a key pillar of discussion. Increasingly, people recognize the impact it is already having on innovation and growth. I believe that we will see in the months ahead companies ...

QUEBEC CITY, March 17, 2026 /PRNewswire/ - OPTEL, a global leader in traceability and compliance solutions, and Kaster ...

A closer look at how robotics is reshaping pharmaceutical manufacturing, from improving quality and compliance to enabling ...

Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

Singapore, February 20, 2026-- AI pharmaceutical-development unicorn Deep Intelligent Pharma has recently completed a new financing round of US$60 million. New investors in this round include Trustar ...

Spread the lovePublic Perception of Drug Costs Recent polling data indicates a significant shift in the American public’s perception of drug pricing, attributing the decline in costs to former ...